7 January 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics", HKEX code: 02256.HK) today announced that the company's Founder and Chief Executive Officer, Dr. Yao-Chang Xu has been invited to lead the business development team and scientific team to attend the 44^th Annual J.P. Morgan Healthcare Conference. The conference will be held from January 12 to 15, 2026, in San Francisco, California, USA.

During the conference, Dr. Yao-Chang Xu; Mr. Roger Xu, Head of BD; Dr. Praveen Kudithipudi, BD Advisor; Dr. Haiyan Ying, Executive Director of Discovery Biology; and Dr. Haibing Deng, Executive Director of Medicinal Chemistry, will engage in in-depth discussions with global investors and potential partners, sharing the company's latest progress in innovative drug development, global strategic expansion, and commercialization efforts, and exploring opportunities for future collaboration.

The J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community, to explore industry trends, capital dynamics, and collaboration opportunities. This prestigious event is expected to host over 8,000 professionals, including executives, investors, and policymakers, are participating in this prestigious event.

For partnership or investment inquiries, please contact:

• Business Development: BD@abbisko.com

• Investor Relations: IR@abbisko.com

About Abbisko Therapeutics

Founded in April 2016, Abbisko Therapeutics Co., Ltd. (HKEX: 02256.HK), is an oncology-focused biopharmaceutical company based in Shanghai that is dedicated to the discovery and development of innovative medicines to treat unmet medical needs in China and globally. The Company was established by a group of seasoned drug hunters with rich research & development and managerial expertise from top multinational pharmaceutical companies. Since its founding, Abbisko Therapeutics has built an extensive pipeline of innovative programs focused on precision oncology and immuno-oncology.

Please visit www.abbisko.com for more information.